Phanes Therapeutics' Spevatamig receives US FDA Fast Track designation in advanced and metastatic biliary tract carcinoma

📅 17/08/2026 00:00 📰 m2pharma 👁️ 2 lectures 🌍 États-Unis 📂 Science

17 August 2026 - Phanes Therapeutics Inc, a California-based, clinical-stage biotech company involved in innovative drug discovery and development in immuno-oncology, announced on Friday that the US F...